-
EMPA-KIDNEY: Introduction to the trial
published: 14 Feb 2019
-
EMPA-KIDNEY results November 2022
published: 04 Nov 2022
-
EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths
The EMPA-KIDNEY trial has demonstrated that empagliflozin reduces the risk of kidney disease progression or death from cardiovascular disease by 28% in people with chronic kidney disease.
Oxford Population Health are a world-leading research institute that investigates the causes and prevention of diseases.
Read more: https://bit.ly/3U7L4j8
published: 04 Nov 2022
-
EMPA-KIDNEY: meta-analysis results
published: 06 Nov 2022
-
EMPA KIDNEY results: Flozins for all CKD with Dr Will Herrington
Will Herrington is a clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He joined the Renal Studies Group as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). In 2013, he was awarded an MD from the University of Cambridge for a thesis entitled ‘The effects of lowering LDL cholesterol on stroke in chronic kidney disease’.
He co-led the EMPA-KIDNEY trial which tested the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes. He co-chairs the UK Kidney Association guideline working group responsible for recommendations on the use of SGLT-2 inhibitors in ad...
published: 17 Jan 2023
-
EMPA CKD - 3 min trial summary
"Link to article: https://www.nejm.org/doi/full/10.1056/NEJMoa2204233
Twitter: https://twitter.com/FralickMike
The Rounds Table Podcast: https://podcasts.apple.com/ca/podcast/the-rounds-table/id826703161
JRNOWL: https://www.jrnowl.com/"
published: 29 Dec 2022
-
Welcome at the Empa Campus in Dübendorf!
Join us on a short lab tour. We will see where new materials are being developed for Switzerland's built infrastructure of tomorrow, how used resources are being brought back into the materials cycle, and where autonomous drones are learning to detect threads to the environment and damage in buildings. We will gain insights into the 3D printing of sensors from renewable materials as well as into atmospheric modelling and the analytics and detection of trace pollutants. Dive with us into the nanosphere as we explore perovskite crystals for new optoelectronic applications and tailored materials for tomorrow's quantum computers. And take a glimpse at the lab where flexible solar cells achieved a(nother) world record in energy conversion efficiency – thus contributing to a sustainable future e...
published: 03 Feb 2022
-
ESC TV On the Road - #AHA22 - DCP and EMPA-KIDNEY trials
Trials covered: DCP and EMPA-KIDNEY
Host: Roser Torra
Guests: Michael Papadakis and Alta Schutte
Our experts - Stephan Achenbach, Carlos Aguiar, Davide Capodanno, David Duncker, Hein Heidbuchel, Nicolle Kraenkel, Carolyn Lam, Francois Mach, Marco Metra, Wilfried Mullens, Michael Papadakis, Eva Prescott, Susanna Price, Alta Schutte, Emma Svennberg and Roser Torra – all join forces as ESC TV delivers insightful opinions on trials released during AHA 2022.
ESC TV takes you there as these key opinion leaders explain the impact on your clinical practice.
More videos here: https://www.escardio.org/Congresses-&-Events/ESC-TV/ESC-TV-on-the-road-at-AHA-2022
---
The video content has been made available for informational and educational purposes only and is aimed at a professional audience. ...
published: 08 Nov 2022
-
नागिन के बदले की कहानी/किसान नाग पूत्र की कथा/किसान ओर नागिन की कहानी
नागिन के बदले की कहानी/किसान नाग पूत्र की कथा/किसान ओर नागिन की कहानी @PoonamKiAwaaz
.
.
#PoonamKiAwaaz
#GeetaRamayan
#HindiKahani
#DharmikKahani
published: 22 Feb 2024
-
Empa: Materials and Technologies to Shape the Future
How will we build and live tomorrow?
With maximum energy efficiency. By using our resources in a sustainable way. In cities worth living in despite climate change.
How do we improve our health and performance?
With intelligent textiles and sensors. With tailor-made implants. With novel therapeutic concepts.
How do we work and travel without fossil fuels?
With climate-neutral energy sources. With flexible solar cells. With innovative energy storage systems.
How do we prevent and reduce the pollution of our environment?
By redesigning technical processes. By analyzing the spread of pollutants. By investigating and minimizing noise.
How do we keep ourselves fit for the future?
With materials for the electronics of tomorrow. Thanks to surfaces with astonishing properties. Through smart technol...
published: 06 Dec 2018
1:52
EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths
The EMPA-KIDNEY trial has demonstrated that empagliflozin reduces the risk of kidney disease progression or death from cardiovascular disease by 28% in people ...
The EMPA-KIDNEY trial has demonstrated that empagliflozin reduces the risk of kidney disease progression or death from cardiovascular disease by 28% in people with chronic kidney disease.
Oxford Population Health are a world-leading research institute that investigates the causes and prevention of diseases.
Read more: https://bit.ly/3U7L4j8
https://wn.com/Empa_Kidney_Results_Empagliflozin_Reduces_Kidney_Disease_Progression_And_Cardiovascular_Deaths
The EMPA-KIDNEY trial has demonstrated that empagliflozin reduces the risk of kidney disease progression or death from cardiovascular disease by 28% in people with chronic kidney disease.
Oxford Population Health are a world-leading research institute that investigates the causes and prevention of diseases.
Read more: https://bit.ly/3U7L4j8
- published: 04 Nov 2022
- views: 4987
1:06:22
EMPA KIDNEY results: Flozins for all CKD with Dr Will Herrington
Will Herrington is a clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephro...
Will Herrington is a clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He joined the Renal Studies Group as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). In 2013, he was awarded an MD from the University of Cambridge for a thesis entitled ‘The effects of lowering LDL cholesterol on stroke in chronic kidney disease’.
He co-led the EMPA-KIDNEY trial which tested the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes. He co-chairs the UK Kidney Association guideline working group responsible for recommendations on the use of SGLT-2 inhibitors in adults with kidney disease and has chaired the UK Renal Trials Network since 2020.
He also aims to better understand the key determinants of kidney disease development and progression using observations from large blood-based prospective cohorts across a wide range of different populations. He has a particular focus on adiposity and its related risk factors, and how these may interlink to also cause cardiovascular disease.
Objectives:
1) Understand the EMPA-KIDNEY trial results
2) Consider how EMPA-KIDNEY fits with the totality of the large-scale flozin trial evidence
3) Explore the absolute benefit and harms of flozins in different types of at risk groups
https://wn.com/Empa_Kidney_Results_Flozins_For_All_Ckd_With_Dr_Will_Herrington
Will Herrington is a clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He joined the Renal Studies Group as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). In 2013, he was awarded an MD from the University of Cambridge for a thesis entitled ‘The effects of lowering LDL cholesterol on stroke in chronic kidney disease’.
He co-led the EMPA-KIDNEY trial which tested the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes. He co-chairs the UK Kidney Association guideline working group responsible for recommendations on the use of SGLT-2 inhibitors in adults with kidney disease and has chaired the UK Renal Trials Network since 2020.
He also aims to better understand the key determinants of kidney disease development and progression using observations from large blood-based prospective cohorts across a wide range of different populations. He has a particular focus on adiposity and its related risk factors, and how these may interlink to also cause cardiovascular disease.
Objectives:
1) Understand the EMPA-KIDNEY trial results
2) Consider how EMPA-KIDNEY fits with the totality of the large-scale flozin trial evidence
3) Explore the absolute benefit and harms of flozins in different types of at risk groups
- published: 17 Jan 2023
- views: 4921
3:21
EMPA CKD - 3 min trial summary
"Link to article: https://www.nejm.org/doi/full/10.1056/NEJMoa2204233
Twitter: https://twitter.com/FralickMike
The Rounds Table Podcast: https://podcasts.apple....
"Link to article: https://www.nejm.org/doi/full/10.1056/NEJMoa2204233
Twitter: https://twitter.com/FralickMike
The Rounds Table Podcast: https://podcasts.apple.com/ca/podcast/the-rounds-table/id826703161
JRNOWL: https://www.jrnowl.com/"
https://wn.com/Empa_Ckd_3_Min_Trial_Summary
"Link to article: https://www.nejm.org/doi/full/10.1056/NEJMoa2204233
Twitter: https://twitter.com/FralickMike
The Rounds Table Podcast: https://podcasts.apple.com/ca/podcast/the-rounds-table/id826703161
JRNOWL: https://www.jrnowl.com/"
- published: 29 Dec 2022
- views: 1049
1:57
Welcome at the Empa Campus in Dübendorf!
Join us on a short lab tour. We will see where new materials are being developed for Switzerland's built infrastructure of tomorrow, how used resources are bein...
Join us on a short lab tour. We will see where new materials are being developed for Switzerland's built infrastructure of tomorrow, how used resources are being brought back into the materials cycle, and where autonomous drones are learning to detect threads to the environment and damage in buildings. We will gain insights into the 3D printing of sensors from renewable materials as well as into atmospheric modelling and the analytics and detection of trace pollutants. Dive with us into the nanosphere as we explore perovskite crystals for new optoelectronic applications and tailored materials for tomorrow's quantum computers. And take a glimpse at the lab where flexible solar cells achieved a(nother) world record in energy conversion efficiency – thus contributing to a sustainable future energy system. Thanks for joining us on our lab tour and see you soon at the Empa Campus in Dübendorf!
https://wn.com/Welcome_At_The_Empa_Campus_In_Dübendorf
Join us on a short lab tour. We will see where new materials are being developed for Switzerland's built infrastructure of tomorrow, how used resources are being brought back into the materials cycle, and where autonomous drones are learning to detect threads to the environment and damage in buildings. We will gain insights into the 3D printing of sensors from renewable materials as well as into atmospheric modelling and the analytics and detection of trace pollutants. Dive with us into the nanosphere as we explore perovskite crystals for new optoelectronic applications and tailored materials for tomorrow's quantum computers. And take a glimpse at the lab where flexible solar cells achieved a(nother) world record in energy conversion efficiency – thus contributing to a sustainable future energy system. Thanks for joining us on our lab tour and see you soon at the Empa Campus in Dübendorf!
- published: 03 Feb 2022
- views: 1276
5:38
ESC TV On the Road - #AHA22 - DCP and EMPA-KIDNEY trials
Trials covered: DCP and EMPA-KIDNEY
Host: Roser Torra
Guests: Michael Papadakis and Alta Schutte
Our experts - Stephan Achenbach, Carlos Aguiar, Davide Capodan...
Trials covered: DCP and EMPA-KIDNEY
Host: Roser Torra
Guests: Michael Papadakis and Alta Schutte
Our experts - Stephan Achenbach, Carlos Aguiar, Davide Capodanno, David Duncker, Hein Heidbuchel, Nicolle Kraenkel, Carolyn Lam, Francois Mach, Marco Metra, Wilfried Mullens, Michael Papadakis, Eva Prescott, Susanna Price, Alta Schutte, Emma Svennberg and Roser Torra – all join forces as ESC TV delivers insightful opinions on trials released during AHA 2022.
ESC TV takes you there as these key opinion leaders explain the impact on your clinical practice.
More videos here: https://www.escardio.org/Congresses-&-Events/ESC-TV/ESC-TV-on-the-road-at-AHA-2022
---
The video content has been made available for informational and educational purposes only and is aimed at a professional audience. It only represents the views and opinions of the original creators of such content.
The information contained in the video has not been approved by the French National Agency for the Safety of Medicines and Health Products (ANSM). Always seek the advice of your physician or another qualified health care provider with any questions you may have regarding a medical condition.
https://www.escardio.org
https://wn.com/Esc_Tv_On_The_Road_Aha22_Dcp_And_Empa_Kidney_Trials
Trials covered: DCP and EMPA-KIDNEY
Host: Roser Torra
Guests: Michael Papadakis and Alta Schutte
Our experts - Stephan Achenbach, Carlos Aguiar, Davide Capodanno, David Duncker, Hein Heidbuchel, Nicolle Kraenkel, Carolyn Lam, Francois Mach, Marco Metra, Wilfried Mullens, Michael Papadakis, Eva Prescott, Susanna Price, Alta Schutte, Emma Svennberg and Roser Torra – all join forces as ESC TV delivers insightful opinions on trials released during AHA 2022.
ESC TV takes you there as these key opinion leaders explain the impact on your clinical practice.
More videos here: https://www.escardio.org/Congresses-&-Events/ESC-TV/ESC-TV-on-the-road-at-AHA-2022
---
The video content has been made available for informational and educational purposes only and is aimed at a professional audience. It only represents the views and opinions of the original creators of such content.
The information contained in the video has not been approved by the French National Agency for the Safety of Medicines and Health Products (ANSM). Always seek the advice of your physician or another qualified health care provider with any questions you may have regarding a medical condition.
https://www.escardio.org
- published: 08 Nov 2022
- views: 701
20:34
नागिन के बदले की कहानी/किसान नाग पूत्र की कथा/किसान ओर नागिन की कहानी
नागिन के बदले की कहानी/किसान नाग पूत्र की कथा/किसान ओर नागिन की कहानी @PoonamKiAwaaz
.
.
#PoonamKiAwaaz
#GeetaRamayan
#HindiKahani
#DharmikKahani
नागिन के बदले की कहानी/किसान नाग पूत्र की कथा/किसान ओर नागिन की कहानी @PoonamKiAwaaz
.
.
#PoonamKiAwaaz
#GeetaRamayan
#HindiKahani
#DharmikKahani
https://wn.com/नागिन_के_बदले_की_कहानी_किसान_नाग_पूत्र_की_कथा_किसान_ओर_नागिन_की_कहानी
नागिन के बदले की कहानी/किसान नाग पूत्र की कथा/किसान ओर नागिन की कहानी @PoonamKiAwaaz
.
.
#PoonamKiAwaaz
#GeetaRamayan
#HindiKahani
#DharmikKahani
- published: 22 Feb 2024
- views: 51
3:01
Empa: Materials and Technologies to Shape the Future
How will we build and live tomorrow?
With maximum energy efficiency. By using our resources in a sustainable way. In cities worth living in despite climate chan...
How will we build and live tomorrow?
With maximum energy efficiency. By using our resources in a sustainable way. In cities worth living in despite climate change.
How do we improve our health and performance?
With intelligent textiles and sensors. With tailor-made implants. With novel therapeutic concepts.
How do we work and travel without fossil fuels?
With climate-neutral energy sources. With flexible solar cells. With innovative energy storage systems.
How do we prevent and reduce the pollution of our environment?
By redesigning technical processes. By analyzing the spread of pollutants. By investigating and minimizing noise.
How do we keep ourselves fit for the future?
With materials for the electronics of tomorrow. Thanks to surfaces with astonishing properties. Through smart technologies that ease our lives.
Empa - The Place where Innovation Starts
www.empa.ch
https://wn.com/Empa_Materials_And_Technologies_To_Shape_The_Future
How will we build and live tomorrow?
With maximum energy efficiency. By using our resources in a sustainable way. In cities worth living in despite climate change.
How do we improve our health and performance?
With intelligent textiles and sensors. With tailor-made implants. With novel therapeutic concepts.
How do we work and travel without fossil fuels?
With climate-neutral energy sources. With flexible solar cells. With innovative energy storage systems.
How do we prevent and reduce the pollution of our environment?
By redesigning technical processes. By analyzing the spread of pollutants. By investigating and minimizing noise.
How do we keep ourselves fit for the future?
With materials for the electronics of tomorrow. Thanks to surfaces with astonishing properties. Through smart technologies that ease our lives.
Empa - The Place where Innovation Starts
www.empa.ch
- published: 06 Dec 2018
- views: 19908